vestimИзвестия Национальной академии наук Беларуси. Серия медицинских наукProceedings of the National Academy of Sciences of Belarus, Medical series1814-60232524-2350The Republican Unitary Enterprise Publishing House "Belaruskaya Navuka"10.29235/1814-6023-2021-18-1-109-116vestim-738Research ArticleОБЗОРЫREVIEWSМетоды медикаментозной терапии хронических дистрофических заболеваний глазной поверхностиMethods of drug therapy for severe dry eye diseasehttps://orcid.org/0000-0002-8505-8273СемакГ. Р.SemakG. R.

Семак Галина Романовна ‒ канд. мед. наук, доцент

пр. Дзержинского, 83, 220116, г. Минск, Республика Беларусь

Galina R. Semak ‒ Ph. D. (Med.), Associate Professor

83, Dzerzhinski Ave., 220116, Minsk, Republic of Belarus

semakgalina@mail.ruБелорусский государственный медицинский университетBelarusian State Medical University202123022021181109116Copyright © Семак Г.Р., 20212021Семак Г.Р.Semak G.R.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://vestimed.belnauka.by/jour/article/view/738

Лечение хронических дистрофических заболеваний глазной поверхности всегда требует сопутствующей коррекции болезни сухого глаза (БСГ) тяжелой степени. Целью настоящей публикации явился анализ литературных данных, иллюстрирующих современные направления развития медикаментозной терапии хронических дистрофических заболеваний глазной поверхности, сопровождающихся тяжелой БСГ нешегреновской этиологии.

Поиск тематических публикаций осуществлялся в базе данных PubMed. По запросу «(dry-eye-disease AND treatment) NOT Sjögren» (фильтр: клинические исследования, рандомизированные контролируемые клинические исследования, метаанализы) за период с 2019 г. было найдено 56 результатов.

В обзор былo включенo 11 публикаций, описывающих результаты клинических исследований эффективности медикаментозных методов в лечении хронических дистрофический заболеваний роговицы.

В лечении БСГ тяжелой степени превалирующим направлением исследования является купирование воспаления в тканях глазной поверхности. Из нестероидных иммуномодулирующих препаратов наиболее часто изучались циклоспорин, а том числе в виде наноэмульсии, диквафосол и бевацизумаб. Была доказана их эффективность и безопасность. В Республике Беларусь нет единого подхода к ведению пациентов с тяжелой и коморбидной БСГ. Основным направлением является активация регенеративных процессов. При этом высокую эффективность демонстрирует плазма, обогащенная ростовыми факторами тромбоцитов, и субконъюнктивальное введение низкомолекулярного натрия гиалуроната.

Treatment of chronic dystrophic diseases of the ocular surface always requires concomitant correction of severe dry eye disease (DED). The purpose of this publication was to analyze the literature data illustrating the current trends in the development of drug therapy for severe dry eye disease of non-Shegren’s etiology.

The search for thematic publications was carried out in the PubMed database. The query “(dry-eye-disease AND treatment) NOT Sjögren” (filter: clinical trials, randomized controlled clinical trials, meta-analyzes) found 56 results since 2019.

The review included 11 publications describing the results of clinical studies of the effectiveness of drug methods in the treatment of severe DED.

In the treatment of severe DED, the prevailing direction of research is the relief of inflammation in the ocular surface tissues. Among the non-steroidal immunomodulatory drugs, the majority of studies were dedicated to cyclosporine, including its nanoemulsion form, diquafosol and bevacizumab. Their effectiveness and safety have been proven. In the Republic of Belarus, there is no unified approach to the management of patients with severe and comorbid DED. The main focus is on the activation of regenerative processes. Platelet rich plasma and subconjunctival administration of low molecular weight sodium hyaluronate demonstrated high efficiency.

дистрофические заболевания глазной поверхностиболезнь сухого глазаплазмаобогащенная ростовыми факторами тромбоцитовциклоспориндиквафосолгиалуроновая кислотаdystrophic diseases of the ocular surfacedry eye diseaseplatelet rich plasmacyclosporinediquafosolhyaluronic acidReferencesTFOS DEWS II definition and classification report / J. P. Craig [et al.] // Ocul. Surf. – 2017. – Vol. 15, N 3. – P. 276–283. https://doi.org/10.1016/j.jtos.2017.05.008Craig J. P., Nichols K. K., Akpek E. K., Caffery B., Dua H. S., Joo C.-K. [et al.]. TFOS DEWS II definition and classification report. Ocular Surface, 2017, vol. 15, no. 3, pp. 276–283. https://doi.org/10.1016/j.jtos.2017.05.008TFOS DEWS II epidemiology report / F. Stapleton [et al.] // Ocul. Surf. – 2017. – Vol. 15, N 3. – P. 334–365. https://doi.org/10.1016/j.jtos.2017.05.003Stapleton F., Alves M., Bunya V. Y., Jalbert I., Lekhanont K., Malet F. [et al.]. TFOS DEWS II epidemiology report. Ocular Surface, 2017, vol. 15, no. 3, pp. 334–365. https://doi.org/10.1016/j.jtos.2017.05.003Nam, K. Efficacy and safety of topical 3 % diquafosol ophthalmic solution for the treatment of multifactorial dry eye disease: meta-analysis of randomized clinical trials / K. Nam, H. J. Kim, A. Yoo // Ophthalm. Res. – 2019. – Vol. 61, N 4. – P. 188–198. https://doi.org/10.1159/000492896Nam K., Kim H. J., Yoo A. Efficacy and safety of topical 3 % diquafosol ophthalmic solution for the treatment of multifactorial dry eye disease: meta-analysis of randomized clinical trials. Ophthalmic Research, 2019, vol. 61, no. 4, pp. 188–198. https://doi.org/10.1159/000492896Effectiveness of using preservative-free artificial tears versus preserved lubricants for the treatment of dry eyes: a systematic review / M. V. M. R. Ribeiro [et al.] // Arq. Bras. Oftalmol. – 2019. – Vol. 82, N 5. – P. 436–445. https://doi.org/10.5935/0004-2749.20190097Ribeiro M. V. M. R., Barbosa F. T., Ribeiro L. E. F., de Sousa-Rodrigues C. F., Ribeiro E. A. N. Effectiveness of using preservative-free artificial tears versus preserved lubricants for the treatment of dry eyes : a systematic review. Arquivos brasileiros de Oftalmologia, 2019, vol. 82, no. 5, pp. 436–445. https://doi.org/10.5935/0004-2749.20190097Safarzadeh, M. Comparison of the clinical efficacy of preserved and preservative-free hydroxypropyl methylcellulosedextran- containing eyedrops / M. Safarzadeh, P. Azizzadeh, P. Akbarshahi // J. Optometry. – 2017. – Vol. 10, N 4. – P. 258–264. https://doi.org/10.1016/j.optom.2016.11.002Safarzadeh M., Azizzadeh P., Akbarshahi P. Comparison of the clinical efficacy of preserved and preservative-free hydroxypropyl methylcellulose-dextran-containing eyedrops. Journal of Optometry, 2017, vol. 10, no. 4, pp. 258–264. https://doi.org/10.1016/j.optom.2016.11.002Nelson, J. D. Sodium hyaluronate and polyvinyl alcohol artificial tear preparations: a comparison in patients with keratoconjunctivitis sicca / J. D. Nelson, R. L. Farris // Arch. Ophthalmol. – 1988. – Vol. 106, N 4. – P. 484–487. https://doi.org/10.1001/archopht.1988.01060130530029Nelson J. D., Farris R. L. Sodium hyaluronate and polyvinyl alcohol artificial tear preparations: a comparison in patients with keratoconjunctivitis sicca. Archives of Ophthalmology, 1988, vol. 106, no. 4, pp. 484–487. https://doi.org/10.1001/archopht.1988.01060130530029Nam, K. Efficacy and safety of topical 3 % diquafosol ophthalmic solution for the treatment of multifactorial dry eye disease: meta-analysis of randomized clinical trials / K. Nam, H. J. Kim, A. Yoo // Ophthalm. Res. – 2019. – Vol. 61, N 4. – P. 188–198. https://doi.org/10.1159/000492896Nam K., Kim H. J., Yoo A. Efficacy and safety of topical 3 % diquafosol ophthalmic solution for the treatment of multifactorial dry eye disease: meta-analysis of randomized clinical trials. Ophthalmic Research, 2019, vol. 61, no. 4, pp. 188–198. https://doi.org/10.1159/000492896Efficacy and safety of treatment of hyposecretory dry eye with platelet-rich plasma / V. Garcia-Conca [et al.] // Acta Ophthalmol. – 2019. – Vol. 97, N 2. – P. e170–e178. https://doi.org/10.1111/aos.13907Garcia-Conca V., Abad-Collado M., Hueso-Abancens J. R., Mengual-Verdú E., Piñero D. P., Aguirre-Balsalobre F., Molina J. C. Efficacy and safety of treatment of hyposecretory dry eye with platelet-rich plasma. Acta Ophthalmologica, 2019, vol. 97, no. 2, pp. e170–e178. https://doi.org/10.1111/aos.13907Effect of recombinant human nerve growth factor eye drops in patients with dry eye: a phase IIa, open label, multiple-dose study / M. Sacchetti [et al.] // Br. J. Ophthalmol. – 2020. – Vol. 104, N 1. – P. 127–135. https://doi.org/10.1136/bjophthalmol-2018-312470Sacchetti M., Lambiase A., Schmidl D., Schmetterer L., Ferrari M., Mantelli F., Allegretti M., Garhoefer G. Effect of recombinant human nerve growth factor eye drops in patients with dry eye: a phase IIa, open label, multiple-dose study. British Journal of Ophthalmology, 2020, vol. 104, no. 1, pp. 127–135. https://doi.org/10.1136/bjophthalmol-2018-312470Efficacy of topical cyclosporine nanoemulsion 0.05 % compared with topical cyclosporine emulsion 0.05 % and diquafosol 3 % in dry eye / C. H. Park [et al.] // Korean J. Ophthalmol. – 2019. – Vol. 33, N 4. – P. 343–352. https://doi.org/10.3341/kjo.2018.0116Park C. H., Kim M. K., Kim E. C., Kim J. Y., Kim T. I., Kim H. K. [et al.]. Efficacy of topical cyclosporine nanoemulsion 0.05 % compared with topical cyclosporine emulsion 0.05 % and diquafosol 3 % in dry eye. Korean Journal of Ophthalmology, 2019, vol. 33, no. 4, pp. 343–352. https://doi.org/10.3341/kjo.2018.0116Evaluation of an enhanced viscosity artificial tear for moderate to severe dry eye disease: a multicenter, double-masked, randomized 30-day study / C. Lievens [et al.] // Cont. Lens Anterior Eye. – 2019. – Vol. 42, N 4. – P. 443–449. https://doi.org/10.1016/j.clae.2018.12.003Lievens C., Berdy G., Douglass D., Montaquila S., Lin H., Simmons P., Carlisle-Wilcox C., Vehige J., Haque S. Evaluation of an enhanced viscosity artificial tear for moderate to severe dry eye disease: a multicenter, double-masked, randomized 30-day study. Contact Lens and Anterior Eye, 2019, vol. 42, no. 4, pp. 443–449. https://doi.org/10.1016/j.clae.2018.12.003Efficacy of topical bevacizumab 0.05 % eye drops in dry eye disease: a double-masked, randomized trial / N. Kasetsuwan [et al.] // PLoS ONE. – 2020. – Vol. 15, N 6. – P. e0234186. https://doi.org/10.1371/journal.pone.0234186Kasetsuwan N., Chantaralawan K., Reinprayoon U., Uthaithammarat L. Efficacy of topical bevacizumab 0.05 % eye drops in dry eye disease: a double-masked, randomized trial. PLoS ONE, 2020, vol. 15, no. 6, p. e0234186. https://doi.org/10.1371/journal.pone.0234186TFOS DEWS II Management and Therapy Report / L. Jones [et al.] // Ocular Surface. – 2017. – Vol. 15, N 3. – P. 575–628. https://doi.org/10.1016/j.jtos.2017.05.006Jones L., Downie L. E., Korb D., Benitez-del-Castillo J. M., Dana R., Deng S. X. [et al.]. TFOS DEWS II Management and Therapy Report. Ocular Surface, 2017, vol. 15, no. 3, pp. 575–628. https://doi.org/10.1016/j.jtos.2017.05.006The role of the lacrimal functional unit in the pathophysiology of dry eye / M. E. Stern [et al.] // Exp. Eye Res. – 2004. – Vol. 78, N 3. – P. 409–416. https://doi.org/10.1016/j.exer.2003.09.003Stern M. E., Gao J., Siemasko K. F., Beuerman R. W., Pflugfelder S. C. The role of the lacrimal functional unit in the pathophysiology of dry eye. Experimental Eye Research, 2004, vol. 78, no. 3, pp. 409–416. https://doi.org/10.1016/j.exer.2003.09.003TFOS DEWS II Pathophysiology Report / A. J. Bron [et al.] // Ocular Surface. – 2017. – Vol. 15, N 3. – P. 438–510. https://doi.org/10.1016/j.jtos.2017.05.011Bron A. J., de Paiva C. S., Chauhan S. K., Bonini S., Gabison E. E., Jain S. TFOS DEWS II pathophysiology report. Ocular Surface, 2017, vol. 15, no. 3, pp. 438–510. https://doi.org/10.1016/j.jtos.2017.05.011Comparison of topical dry eye medications for the treatment of keratoconjunctivitis sicca in a botulinum toxin B-induced mouse model / K. Lekhanont [et al.] // Cornea. – 2007. – Vol. 26, N 1. – P. 84–89. https://doi.org/10.1097/01.ico.0000240079.24583.a1Lekhanont K., Leyngold I., Suwan-Apichon O., Rangsin R., Chuck R. S. Comparison of topical dry eye medications for the treatment of keratoconjunctivitis sicca in a botulinum toxin B-induced mouse model. Cornea, 2007, vol. 26, no. 1, pp. 84–89. https://doi.org/10.1097/01.ico.0000240079.24583.a1Tetrasodium increases the concentration of mucin-like substances in tears of healthy human subjects / Chika Shigeyasu [et al.] // Curr. Eye Res. – 2015. – Vol. 40, N 9. – P. 878–883. https://doi.org/10.3109/02713683.2014.967871Chika Shigeyasu, Shinichiro Hirano, Yoko Akune, Masakazu Yamada. Diquafosol tetrasodium increases the concentration of mucin-like substances in tears of healthy human subjects. Current Eye Research, 2015, vol. 40, no. 9, pp. 878–883. https://doi.org/10.3109/02713683.2014.967871A randomised, parallel-group comparison study of diquafosol ophthalmic solution in patients with dry eye in China and Singapore / L. Gong [et al.] // Br. J. Ophthalmol. – 2015. – Vol. 99, N 7. – P. 903–908. https://doi.org/10.1136/bjophthalmol-2014-306084Gong L, Sun X, Ma Z. [et al]. A randomised, parallel-group comparison study of diquafosol ophthalmic solution in patients with dry eye in China and Singapore. British Journal of Ophthalmology, 2015, vol. 99, no. 7, pp. 903–908. https://doi.org/10.1136/bjophthalmol-2014-306084Additive effect of preservative-free sodium hyaluronate 0.1 % in treatment of dry eye syndrome with diquafosol 3 % eye drops / H. S. Hwang [et al.] // Cornea. – 2014. – Vol. 33, N 9. – P. 935–941. https://doi.org/10.1097/ico.0000000000000213Hwang H. S., Sung Y.-M., Lee W. S., Kim E. C. Additive effect of preservative-free sodium hyaluronate 0.1 % in treatment of dry eye syndrome with diquafosol 3 % eye drops. Cornea, 2014, vol. 33, no. 9, pp. 935–941. https://doi.org/10.1097/ico.0000000000000213Clinical evaluation of the additive effect of diquafosol tetrasodium on sodium hyaluronate monotherapy in patients with dry eye syndrome: a prospective, randomized, multicenter study / K. Kamiya [et al.] // Eye. – 2012. – Vol. 26, N 10. – P. 1363–1368. https://doi.org/10.1038/eye.2012.166Kamiya K., Nakanishi M., Ishii R., Kobashi H., Igarashi A., Sato N., Shimizu K. Clinical evaluation of the additive effect of diquafosol tetrasodium on sodium hyaluronate monotherapy in patients with dry eye syndrome: a prospective, randomized, multicenter study. Eye, 2012, vol. 26, no. 10, pp. 1363–1368. https://doi.org/10.1038/eye.2012.166Systematic review of randomised clinical trials on topical ciclosporin A for the treatment of dry eye disease / M. Sacchetti [et al.] // Br. J. Ophthalmol. – 2014. – Vol. 98, N 8. – P. 1016–1022. https://doi.org/10.1136/bjophthalmol-2013-304072Sacchetti M., Mantelli F., Lambiase A., Mastropasqua A., Merlo D., Bonini S. Systematic review of randomised clinical trials on topical ciclosporin A for the treatment of dry eye disease. British Journal of Ophthalmology, 2014, vol. 98, no. 8, pp. 1016–1022. https://doi.org/10.1136/bjophthalmol-2013-304072Efficacy of topical bevacizumab 0.05 % eye drops in dry eye disease: A double-masked, randomized trial / N. Kasetsuwan [et al.] // PLoS ONE. – 2020. – Vol. 15, N 6. – P. e0234186. https://doi.org/10.1371/journal.pone.0234186Kasetsuwan N., Chantaralawan K., Reinprayoon U., Uthaithammarat L. Efficacy of topical bevacizumab 0.05 % eye drops in dry eye disease: a double-masked, randomized trial. PLoS ONE, 2020, vol. 15, no. 6, p. e0234186. https://doi.org/10.1371/journal.pone.0234186Effect of recombinant human nerve growth factor eye drops in patients with dry eye: a phase IIa, open label, multiple-dose study / M. Sacchetti [et al.] // Br. J. Ophthalmol. – 2020. – Vol. 104, N 1. – P. 127–135. https://doi.org/10.1136/bjophthalmol-2018-312470Sacchetti M., Lambiase A., Schmidl D., Schmetterer L., Ferrari M., Mantelli F., Allegretti M., Garhoefer G. Effect of recombinant human nerve growth factor eye drops in patients with dry eye: a phase IIa, open label, multiple-dose study. British Journal of Ophthalmology, 2020, vol. 104, no. 1, pp. 127–135. https://doi.org/10.1136/bjophthalmol-2018-312470Blood-based treatments for severe dry eye disease: the need of a consensus / F. Bernabei [et al.] // J. Clin. Med. – 2019. – Vol. 8, N 9. – P. 1478. https://doi.org/10.3390/jcm8091478Bernabei F., Roda M., Buzzi M., Pellegrini M., Giannaccare G., Versura P. Blood-based treatments for severe dry eye disease: the need of a consensus. Journal of Clinical Medicine, 2019, vol. 8, no. 9, p. 1478. https://doi.org/10.3390/jcm8091478Семак, Г. Р. Низкомолекулярная гиалуроновая кислота в лечении кератопатии на фоне глаукомы [Электронный ресурс] / Г. Р. Семак, И. Ю. Жерко // Достижения медицинской науки Беларуси – 2019. – Режим доступа: http://med.by/dmn/book.php?book=19-14_9. – Дата доступа: 09.03.2020.Semak G. R., Zherko I. Yu. Low molecular weight hyaluronic acid in the treatment of keratopathy with glaucoma. Achievements of the medical science of Belarus – 2019. Available at: http://med.by/dmn/book.php?book=19-14_9 (accessed 09.03.2020) (in Russian).Особенности экспрессии биомолекулярных маркеров (CD44, mmp9, TGFβ1) в оценке эффективности лечения эндотелиально-эпителиальной дистрофии роговицы / Г. Р. Семак [и др.] // Вес. Нац. акад. навук Беларусi. Сер. мед. навук. – 2019. – Т. 16, № 4. – P. 477–487.Semak G. R., Zakharova V. A., Kletskii S. K., Letkovskaya T. A., Zherko I. Yu. Features of the biomolecular markers expression (CD44, MMP9, TGFβ1) in assessing the effectiveness of the endothelial-epithelial corneal dystrophy treatment. Vestsi Natsyyanal’nai akademii navuk Belarusi. Seryya medytsynskіkh navuk = Proceedings of the National Academy of Sciences of Belarus. Medical series, 2019, vol. 16, no. 4, pp. 477–487 (in Russian).Семак, Г. Р. Клинические результаты использования препаратов гиалуроновой кислоты в лечении кератопатии / Г. Р. Семак, И. Ю. Жерко, Н. Г. Розуванова // Офтальмология. Вост. Европа. – 2019. – Т. 9, № 2. – С. 237–245.Semak G. R., Zherko I. Yu., Rozuvanova N. G. Clinical results of the hyaluronic acid use in the treatment of keratopathy. Oftal’mologiya. Vostochnaya Evropa [Ophthalmology. Eastern Europe], 2019, vol. 9, no. 2, pp. 237–245 (in Russian).

The authors declare that there are no conflicts of interest present.